Organon Gains Access To Two Databases in Partnership with Incyte | GenomeWeb

PALO ALTO, Calif.--Incyte Pharmaceuticals here has signed a multiyear database partnership agreement with Organon, a pharmaceutical business unit of Akzo Nobel. The deal will give Organon access to Incyte's LifeSeq gene sequence and expression database and its LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon will be responsible for developing and commercializing any drugs that arise from the collaboration, but Incyte could receive royalties on sales developed with its technology and databases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.